Cargando…

Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer

Oncogenic KRAS has been previously identified to act in a cell-intrinsic manner to modulate multiple biological functions of colorectal cancer (CRC). Here, we demonstrate a cell-extrinsic role of KRAS, where KRAS engages with the tumor microenvironment by functional reprogramming of tumor-associated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Huashan, Liang, Zhenxing, Zhou, Chi, Zeng, Ziwei, Wang, Fengwei, Hu, Tuo, He, Xiaowen, Wu, Xiaojian, Wu, Xianrui, Lan, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032794/ https://www.ncbi.nlm.nih.gov/pubmed/33833221 http://dx.doi.org/10.1038/s41392-021-00534-2

Ejemplares similares

Cyr61 from adipose‐derived stem cells promotes colorectal cancer metastasis and vasculogenic mimicry formation via integrin α(V)β(5)
por: Liang, Zhenxing, et al.
Publicado: (2021)

Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T‐Cells to Activation‐Induced Cell Death in Colorectal Cancer
por: Liu, Huashan, et al.
Publicado: (2023)

Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis
por: Hu, Tuo, et al.
Publicado: (2020)

Incidence and risk factors for incisional surgical site infection in patients with Crohn’s disease undergoing bowel resection
por: Hu, Tuo, et al.
Publicado: (2018)

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
por: Kerr, Emma, et al.
Publicado: (2016)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
por: Suzuki, Tatsunori, et al.
Publicado: (2021)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
por: Cheon, Seul‐Ki, et al.
Publicado: (2018)

Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers
por: Yang, Xin, et al.
Publicado: (2022)

A novel cell‐free DNA methylation‐based model improves the early detection of colorectal cancer
por: Wu, Xianrui, et al.
Publicado: (2021)

Integrated multi-omics characterization of KRAS mutant colorectal cancer
por: Chong, Wei, et al.
Publicado: (2022)

Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations
por: Hammond, Dean E., et al.
Publicado: (2015)

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer
por: Hiraki, Masayuki, et al.
Publicado: (2015)

Engulfment and cell motility protein 1 fosters reprogramming of tumor‐associated macrophages in colorectal cancer
por: Wen, Bo, et al.
Publicado: (2022)

Safety and Efficacy of Sodium Hyaluronate Gel and Chitosan in Preventing Postoperative Peristomal Adhesions After Defunctioning Enterostomy: A Prospective Randomized Controlled Trials
por: Hu, Jiancong, et al.
Publicado: (2015)

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2014)

Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis
por: Park, Sujeong, et al.
Publicado: (2018)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
por: Zhong, Longhui, et al.
Publicado: (2020)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
por: Liu, Jungang, et al.
Publicado: (2021)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
por: Naseem, Madiha, et al.
Publicado: (2021)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Preoperative hypoalbuminemia is associated with an increased risk for intra-abdominal septic complications after primary anastomosis for Crohn’s disease
por: Liu, Xuanhui, et al.
Publicado: (2017)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy
por: Alves, Sara, et al.
Publicado: (2015)

MICA (∗)012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer
por: Ding, Weifeng, et al.
Publicado: (2020)

m(6)A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways
por: Deng, Ru, et al.
Publicado: (2019)

Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
por: Zhou, Qiming, et al.
Publicado: (2023)

KRAS mutant–driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer
por: Luo, Yuming, et al.
Publicado: (2022)

Dual inhibition of CDK4 and FYN leads to selective cell death in KRAS-mutant colorectal cancer
por: Wang, Yan, et al.
Publicado: (2019)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
por: Wong, Chi Chun, et al.
Publicado: (2022)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation
por: Shen, Chih-Jie, et al.
Publicado: (2023)

In vivo reprogramming drives Kras-induced cancer development
por: Shibata, Hirofumi, et al.
Publicado: (2018)

Rab13 regulates sEV secretion in mutant KRAS colorectal cancer cells
por: Hinger, Scott A., et al.
Publicado: (2020)

Targeting oxidative pentose phosphate pathway prevents recurrence in mutant Kras colorectal carcinomas
por: Gao, WenChao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qogm1b5uv63lqd7sju72cv2q59